Key result
Perioperative IV magnesium sulfate fails to reduce POAF compared to placebo.
Why the study?
To determine whether perioperative IV magnesium sulfate infusion, targeting serum magnesium concentrations of 1.5-2.0 mmol/L, reduces postoperative atrial fibrillation in cardiac surgery patients.
Does perioperative IV magnesium sulfate infusion reduce the incidence of postoperative atrial fibrillation in adult patients undergoing cardiac surgery?
RCT (n=265)
Double-blind
No
Does perioperative IV magnesium sulfate infusion reduce the incidence of postoperative atrial fibrillation in adult patients undergoing cardiac surgery?
Perioperative intravenous magnesium sulfate infusion does not reduce the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery, challenging the routine use of prophylactic magnesium.
Answers are grounded in this paper and cite their sources.
Magnesium sulfate does not reduce POAF after cardiac surgery; confirms futility and supports avoiding routine use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Meerman et al. (2026) conducted an RCT in Postoperative atrial fibrillation in cardiac surgery (n=265). Magnesium sulfate vs. Placebo (Ringer's lactate) was evaluated on Incidence of postoperative atrial fibrillation (POAF) (RR 1.29, 95% CI 0.92-1.80). Perioperative IV magnesium sulfate infusion did not reduce postoperative atrial fibrillation compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: